NovoCure Ltd.
64
9
14
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
31.3%
20 terminated/withdrawn out of 64 trials
51.2%
-35.3% vs industry average
8%
5 trials in Phase 3/4
76%
16 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (64)
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
Role: lead
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Role: collaborator
A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
Role: collaborator
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Role: collaborator
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
Role: lead
WBSI Guided Personalized Delivery of TTFields
Role: collaborator
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Role: collaborator
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Role: collaborator
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
Role: collaborator
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Role: collaborator
Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma
Role: collaborator
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
Role: collaborator
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Role: lead
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
Role: collaborator
Niraparib/TTFields in GBM
Role: collaborator
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Role: collaborator
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Role: collaborator
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Role: collaborator
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
Role: lead
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
Role: collaborator